Pre-IPO Anduril Stock Climbs 50% in 5 Months

Anduril’s reported private-market valuation has risen to roughly $90 billion, up 48% in five months and about threefold since June 2025. Reuters estimates the defense technology company is on track for $4.3 billion in sales this year but will lose $1 billion; the valuation implies about 21 times sales. The article argues that valuation looks excessive, particularly as Anduril plans to spend $3.7 billion on a shipyard, while noting the company’s growth and defense-industry ambitions.

Analysis

The key risk is not whether Anduril can grow, but whether growth converts into cash before the business absorbs substantially more capital. A high private tender mark is weak price discovery: employee liquidity, limited float and financing preferences can make it a poor guide to an IPO clearing price. The planned shipyard raises the bar further—investors should distinguish contracted demand from funded, deliverable work and track cash burn, capex and working-capital needs, not just bookings or revenue.

Near term, this is not a clean read-through to listed defense stocks. If Anduril takes share, incumbent contractors could face pressure on selected programs and pricing; if its lower-cost products expand the addressable defense budget, the effect may instead be market growth rather than simple share transfer. Neither outcome justifies a sector-wide position from this evidence alone.

Over 1–3 months, the useful catalysts are tender terms, evidence of funded awards, and any IPO filing that reveals customer concentration, backlog quality and capital requirements. Over 6–18 months, execution at the shipyard and a credible path to lower cash burn matter more than private valuation marks. The contrarian case is that rapid scaling and procurement reform could support a premium if repeatable economics emerge; the bear case is that revenue growth masks persistently negative unit economics and capital intensity. A disclosed improvement in cash conversion would weaken the bear thesis; rising capex or weaker funded backlog would strengthen it.

Key Decisions for Investors

• No immediate public-equity trade: Anduril has no listed ticker, and the article does not establish a direct public-market proxy or a measurable earnings impact for named defense contractors.
• Treat any IPO as a watchlist event, not an automatic buy or short. Review the S-1 for funded backlog, customer concentration, gross-profit and cash-conversion trends, capex commitments, and share-sale/lockup structure before sizing exposure.
• If a public listing prices at a premium while cash burn and capital commitments remain elevated, consider waiting through initial price discovery rather than chasing; a short requires borrow availability and a defined risk limit, neither established here.
• Do not infer supplier beneficiaries from the shipyard announcement. Revisit that angle only after the company identifies awarded contracts, project timing and procurement vendors.